Diagnostic criteria for cancer cachexia: Data versus dogma

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 19, Issue 3, 2016, Pages 188-198

  Martin, Lisa ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

Cancer cachexia; Diagnostic criteria; Food intake; Inflammation; Skeletal muscle; Weight loss

Indexed keywords

ANTIQUITY; CACHEXIA; CONSENSUS; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; FOOD INTAKE; HUMAN; INFLAMMATION; METABOLIC DISORDER; REVIEW; SKELETAL MUSCLE; WEIGHT REDUCTION; ANOREXIA; BODY WEIGHT LOSS; CHEMICALLY INDUCED; DRUG EFFECT; EVIDENCE BASED MEDICINE; FATIGUE; INTERNATIONAL COOPERATION; MUSCLE WEAKNESS; NEOPLASM; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

ANTINEOPLASTIC AGENT;

ANOREXIA; ANTINEOPLASTIC AGENTS; CACHEXIA; CONSENSUS; EVIDENCE-BASED MEDICINE; FATIGUE; HUMANS; INTERNATIONAL AGENCIES; MUSCLE WEAKNESS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; SEVERITY OF ILLNESS INDEX; WEIGHT LOSS;

EID: 84960192111     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000272     Document Type: Review

References (50)

1. Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008; 27:793-799.
2. U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v.4.03. 2010 June 14.
3. Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 2006; 83:1345-1350.
4. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus framework. Lancet Oncol 2011; 12:489-495.
5. Jensen GL, Mirtallo J, Compher C, et al. Adult starvation and disease-related malnutrition: a proposal for etiology-based diagnosis in the clinical practice setting from the International Consensus Guideline Committee. JPEN J Parenter Enteral Nutr 2010; 34:156-159.
6. Dechaphunkul T, Martin L, Alberda C, et al. Malnutrition assessment in patients with cancers of the head and neck: a call to action and consensus. Crit Rev Oncol Hematol 2013; 88:459-476.
7. Blum D, Stene GB, Solheim TS, et al. Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model-a study based on data from an international multicentre project (EPCRC-CSA). Ann Oncol 2014; 25:1635-1642.
8. Garcia JM, Boccia RV, Graham CD, et al. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 2015; 16:108-116.
9. Thoresen L, Frykholm G, Lydersen S, et al. Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin Nutr 2013; 32:65-72.
10. Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer 2013; 21:1569-1577.
11. Wesseltoft-Rao N, Hjermstad MJ, Ikdahl T, et al. Comparing two classifications of cancer cachexia and their association with survival in patients with unresected pancreatic cancer. Nutr Cancer 2015; 67:472-480.
12. LeBlanc TW, Nipp RD, Rushing CN, et al. Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced nonsmall cell lung cancer. J Pain Symptom Manage 2015; 49:680-689.
13. Bozzetti F, Cotogni P, Lo VS, et al. Development and validation of a nomogram to predict survival in incurable cachectic cancer patients on home parenteral nutrition. Ann Oncol 2015.
14. Martin L, Senesse P, Gioulbasanis I, et al. Diagnostic criteria for the classification of cancer-associated weight loss. J Clin Oncol 2015; 33:90-99.
15. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69:491-497.
16. Gibson DJ, Burden ST, Strauss BJ, et al. The role of computed tomography in evaluating body composition and the influence of reduced muscle mass on clinical outcome in abdominal malignancy: a systematic review. Eur J Clin Nutr 2015; 69:1079-1086.
17. Kazemi-Bajestani SM, Mazurak VC, Baracos V. Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes. Semin Cell Dev Biol 2015. [Epub ahead of print]. doi: 10.1016/j.semcdb. 2015.09.001.
18. Levolger S, van Vugt JL, de Bruin RW, Ijzermans JN. Systematic review of sarcopenia in patients operated on for gastrointestinal and hepatopancreatobiliary malignancies. Br J Surg 2015; 102:1448-1458.
19. Malietzis G, Aziz O, Bagnall NM, et al. The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: a systematic review. Eur J Surg Oncol 2015; 41:186-196.
20. Sjoblom B, Gronberg BH, Benth JS, et al. Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced nonsmall cell lung cancer. Lung Cancer 2015; 90:85-91.
21. Harada K, Ida S, Baba Y, et al. Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma. Dis Esophagus 2015. doi: 10.1111/dote.12381.
22. Huang DD, Wang SL, Zhuang CL, et al. Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer. Colorectal Dis 2015; 17:O256-O264.
23. Tegels JJ, van Vugt JL, Reisinger KW, et al. Sarcopenia is highly prevalent in patients undergoing surgery for gastric cancer but not associated with worse outcomes. J Surg Oncol 2015; 112:403-407.
24. van Vugt JL, Braam HJ, van Oudheusden TR, et al. Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer. Ann Surg Oncol 2015; 22:3625-3631.
25. Fujiwara N, Nakagawa H, Kudo Y, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 2015; 63:131-140.
26. Fukushima H, Nakanishi Y, Kataoka M, et al. Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma. J Urol 2016; 195:26-32.
27. Psutka SP, Boorjian SA, Moynagh MR, et al. Decreased skeletal muscle mass is associated with an increased risk of mortality after radical nephrectomy for localized renal cell cancer. J Urol 2016; 195:270-276.
28. Tamandl D, Paireder M, Asari R, et al. Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer. Eur Radiol 2015. [Epub ahead of print]. doi: 10.1007/s00330-015-3963-1.
29. Antoun S, Bayar A, Ileana E, et al. High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting. Eur J Cancer 2015; 51:2570-2577.
30. Choi Y, Oh DY, Kim TY, et al. Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index. PLoS One 2015; 10:e0139749.
31. Cooper AB, Slack R, Fogelman D, et al. Characterization of anthropometric changes that occur during neoadjuvant therapy for potentially resectable pancreatic cancer. Ann Surg Oncol 2015; 22:2416-2423.
32. Kimura M, Naito T, Kenmotsu H, et al. Prognostic impact of cancer cachexia in patients with advanced nonsmall cell lung cancer. Support Care Cancer 2015; 23:1699-1708.
33. Miyamoto Y, Baba Y, Sakamoto Y, et al. Negative impact of skeletal muscle loss after systemic chemotherapy in patients with unresectable colorectal cancer. PLoS One 2015; 10:e0129742.
34. Rollins KE, Tewari N, Ackner A, et al. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. Clin Nutr 2015. [Epub ahead of print]. doi: 10.1016/j.clnu. 2015.08.005.
35. Aust S, Knogler T, Pils D, et al. Skeletal muscle depletion and markers for cancer cachexia are strong prognostic factors in epithelial ovarian cancer. PLoS One 2015; 10:e0140403.
36. Malietzis G, Johns N, Al-Hassi HO, et al. Low muscularity and myosteatosis is related to the host systemic inflammatory response in patients undergoing surgery for colorectal cancer. Ann Surg 2016; 263:320-325.
37. Reisinger KW, Derikx JP, van Vugt JL, et al. Sarcopenia is associated with an increased inflammatory response to surgery in colorectal cancer. Clin Nutr 2015. [Epub ahead of print]. doi: 10.1016/j.clnu.2015.07.005.
38. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008; 9:629-635.
39. Martin L, Birdsell L, MacDonald N, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013; 31:1539-1547.
40. Hubbard JM, Cohen HJ, Muss HB. Incorporating biomarkers into cancer and aging research. J Clin Oncol 2014; 32:2611-2616.
41. LeBlanc TW, Samsa GP, Wolf SP, et al. Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced nonsmall cell lung cancer and the cancer anorexia-cachexia syndrome (CACS). Support Care Cancer 2015; 23:2341-2347.
42. Salsman JM, Beaumont JL, Wortman K, et al. Brief versions of the FACITfatigue and FAACT subscales for patients with nonsmall cell lung cancer cachexia. Support Care Cancer 2015; 23:1355-1364.
43. Solheim TS, Blum D, Fayers PM, et al. Weight loss, appetite loss and food intake in cancer patients with cancer cachexia: three peas in a pod? -analysis from a multicenter cross sectional study. Acta Oncol 2014; 53:539-546.
44. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev 2013; 39:534-540.
45. Guthrie GJ, Charles KA, Roxburgh CS, et al. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013; 88:218-230.
46. Simmons CP, Koinis F, Fallon MT, et al. Prognosis in advanced lung cancer-A prospective study examining key clinicopathological factors. Lung Cancer 2015; 88:304-309.
47. Laird BJ, McMillan DC, Fayers P, et al. The systemic inflammatory response and its relationship to pain and other symptoms in advanced cancer. Oncologist 2013; 18:1050-1055.
48. Wallengren O, Iresjo BM, Lundholm K, Bosaeus I. Loss of muscle mass in the end of life in patients with advanced cancer. Support Care Cancer 2015; 23:79-86.
49. Johns N, Tan BH, MacMillan M, et al. Genetic basis of interindividual susceptibility to cancer cachexia: selection of potential candidate gene polymorphisms for association studies. J Genet 2014; 93:893-916.
50. International Expert Committee report on the role of the A1C assay in the diagnosis of, diabetes. Diabetes Care 2009; 32:1327-1334.